LEXARIA BIOSCIENCE CORP (LEXX)
US52886N4060 - Common Stock
Lexaria Bioscience Corp. (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment
LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024
LEXX stock results show that Lexaria Bioscience beat analyst estimates for earnings per share the second quarter of 2024.
LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexaria Bioscience (NASDAQ:LEXX) just reported results for the second quarter o...
Lexaria Awarded New Patents
Lexaria receives new patents in the fields of epilepsy and anti-viral agents
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
Lexaria Bioscience stock falls as it prices its $3.6M offering (NASDAQ:LEXX)
Lexaria Bioscience shares drop 13.5% in pre-market trade after announcing purchase and sale agreements for 1.56M shares at $2.31 each.
Lexaria submits IND to begin Phase 1b study of DehyraTECH-CBD (NASDAQ:LEXX)
Lexaria (LEXX) said it has submitted an IND with the FDA to initiate a Phase 1b study of its drug candidate DehydraTECH-CBD in the treatment of hypertension. Read more here.
LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024
Lexaria Bioscience just reported results for the first quarter of 2024.
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled,...
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
/PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1...
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial...
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
/PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on FDA Application for Investigational Drug
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study
Lexaria Bioscience files to sell 1.62M for its holders (NASDAQ:LEXX)
Lexaria Bioscience (LEXX) filed a prospectus related to the proposed resale of 1.62M common shares by the selling stockholders. This prospectus is not an offer